Role of MRI in prostate cancer detection

The standard approach for the detection of prostate cancer ‐‐ prostate‐specific antigen (PSA) screening followed by transrectal ultrasonography (TRUS)‐guided biopsy ‐‐ has low sensitivity and provides limited information about the true extent and aggressiveness of the cancer. Improved methods are needed to assess the extent and aggressiveness of the cancer and to identify patients who will benefit from therapy. In recent years, there has been tremendous development of acquisition and processing tools for physiological and metabolic MRI techniques which play a potential role in the detection, localization and characterization of prostate cancer, such as dynamic contrast‐enhanced MRI (DCE‐MRI), diffusion‐weighted MRI (DW‐MRI) and/or proton MR spectroscopic imaging (1H MRSI). The standard protocol for prostate MRI without the use of a contrast agent involves multi‐planar T1‐weighted MRI, T2‐weighted MRI and DW‐MRI. This review discusses the potential role of MRI in the detection of prostate cancer, specifically describing the status of MRI as a tool for guiding targeted prostate biopsies and for detecting cancer in the untreated and treated gland. In addition, future areas of MRI research are briefly discussed. Groups conducting clinical trials should consider the recommendations put forward by the European Consensus Meeting, which state that the minimum requirements for prostate MRI are T1‐weighted MRI, T2‐weighted MRI, DCE‐MRI (which involves the use of a contrast agent) and DW‐MRI with a pelvic phased‐array coil and propose the use of transperineal template mapping biopsies as the optimal reference standard. Copyright © 2013 John Wiley & Sons, Ltd.

[1]  N M deSouza,et al.  Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. , 2008, Clinical radiology.

[2]  P. Choyke,et al.  Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. , 2012, Medical physics.

[3]  H. Hricak,et al.  Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer , 2005, Nature Clinical Practice Urology.

[4]  Sadhna Verma,et al.  Imaging-guided prostate biopsy: conventional and emerging techniques. , 2012, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  T. Sone,et al.  Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. , 2011, AJR. American journal of roentgenology.

[6]  H. Hricak,et al.  The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. , 2012, AJR. American journal of roentgenology.

[7]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[8]  H. Hricak,et al.  Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. , 2007, International journal of radiation oncology, biology, physics.

[9]  Piotr Kozlowski,et al.  Diffusion-weighted MRI in prostate cancer -- comparison between single-shot fast spin echo and echo planar imaging sequences. , 2008, Magnetic resonance imaging.

[10]  H. Hricak,et al.  MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. , 2005, The British journal of radiology.

[11]  Yousef Mazaheri,et al.  Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. , 2011, Radiology.

[12]  F. Montorsi,et al.  Prostate cancer detection rates in different biopsy schemes. Which cores for which patients? , 2014, World Journal of Urology.

[13]  Kemal Tuncali,et al.  Image registration for targeted MRI‐guided transperineal prostate biopsy , 2012, Journal of magnetic resonance imaging : JMRI.

[14]  Silvia D. Chang,et al.  Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. , 2002, Radiology.

[15]  Ciprian Catana,et al.  Simultaneous PET-MRI: a new approach for functional and morphological imaging , 2008, Nature Medicine.

[16]  H. Hricak,et al.  Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. , 2006, Radiology.

[17]  Gabor Fichtinger,et al.  A workspace‐orientated needle‐guiding robot for 3T MRI‐guided transperineal prostate intervention: evaluation of in‐bore workspace and MRI compatibility , 2013, The international journal of medical robotics + computer assisted surgery : MRCAS.

[18]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[19]  Yousef Mazaheri,et al.  MRI of the prostate: Clinical relevance and emerging applications , 2011, Journal of magnetic resonance imaging : JMRI.

[20]  Jelle O. Barentsz,et al.  MRI-guided and robotic-assisted prostate biopsy , 2012, Current opinion in urology.

[21]  J Kurhanewicz,et al.  Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging , 2001, Magnetic resonance in medicine.

[22]  Roberto Passariello,et al.  Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. , 2008, European urology.

[23]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[24]  John M Pauly,et al.  High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. , 2006, Magnetic resonance imaging.

[25]  Oguz Akin,et al.  MR imaging of treated prostate cancer. , 2012, Radiology.

[26]  M. Kattan,et al.  The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis , 2007, BJU international.

[27]  J. Kurhanewicz,et al.  Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer , 2012, Journal of magnetic resonance imaging : JMRI.

[28]  B. Carey,et al.  Imaging for prostate cancer. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[29]  P. Carroll,et al.  Magnetic resonance imaging and spectroscopy of prostate cancer. , 2006, Reviews in urology.

[30]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[31]  A. D'Amico,et al.  MRI-guided diagnosis and treatment of prostate cancer. , 2001, The New England journal of medicine.

[32]  Dennis W J Klomp,et al.  Optimal timing for in vivo 1H‐MR spectroscopic imaging of the human prostate at 3T , 2005, Magnetic resonance in medicine.

[33]  Sharyn I. Katz,et al.  MR imaging and MR spectroscopy in prostate cancer management. , 2006, Radiologic clinics of North America.

[34]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[35]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[36]  M. Kattan,et al.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer , 2012, BJU international.

[37]  Jaime Pujadas Oláno,et al.  Natural history of early localized prostate cancer. , 2004, JAMA.

[38]  V. Pansadoro,et al.  Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 2004, La Radiologia medica.

[39]  P. Carroll,et al.  Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. , 1996, AJR. American journal of roentgenology.

[40]  I. Floriani,et al.  Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. , 2008, AJR. American journal of roentgenology.

[41]  Baris Turkbey,et al.  Intravoxel incoherent motion MR imaging for prostate cancer: An evaluation of perfusion fraction and diffusion coefficient derived from different b‐value combinations , 2013, Magnetic resonance in medicine.

[42]  M D Schnall,et al.  Cost-effectiveness of endorectal magnetic resonance imaging for the staging of prostate cancer. , 1996, Academic radiology.

[43]  B. Carey,et al.  Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. , 2011, European urology.

[44]  Lawrence H. Schwartz,et al.  Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results , 2011, European Radiology.

[45]  Baris Turkbey,et al.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. , 2012, AJR. American journal of roentgenology.

[46]  Martijn Smeenge,et al.  Current status of transrectal ultrasound techniques in prostate cancer , 2012, Current opinion in urology.

[47]  Evis Sala,et al.  Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. , 2006, Radiology.

[48]  Martin S Judenhofer,et al.  Applications for preclinical PET/MRI. , 2013, Seminars in nuclear medicine.

[49]  J. Lagendijk,et al.  SAR and power implications of different RF shimming strategies in the pelvis for 7T MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[50]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[51]  H. D. de Koning,et al.  Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam , 2010, Journal of the National Cancer Institute.

[52]  M. Langer,et al.  Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. , 2005, European journal of radiology.

[53]  H. Hricak,et al.  Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations. , 2004, Radiology.

[54]  Wei Huang,et al.  Feasibility of shutter‐speed DCE‐MRI for improved prostate cancer detection , 2013, Magnetic resonance in medicine.

[55]  P. Carroll,et al.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. , 2004, AJR. American journal of roentgenology.

[56]  Baris Turkbey,et al.  Multiparametric MRI and prostate cancer diagnosis and risk stratification , 2012, Current opinion in urology.

[57]  M. Anscher.  PSA kinetics and risk of death from prostate cancer: in search of the Holy Grail of surrogate end points. , 2005, JAMA.

[58]  Raj Persad,et al.  Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? , 2013, Journal of magnetic resonance imaging : JMRI.

[59]  J Kurhanewicz,et al.  Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. , 2001, Radiology.

[60]  H. Hricak,et al.  Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. , 2012, Radiology.

[61]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[62]  Ashutosh Kumar Singh,et al.  Magnetic resonance imaging‐directed transrectal ultrasonography‐guided biopsies in patients at risk of prostate cancer , 2007, BJU international.

[63]  Reducing the influence of b‐value selection on diffusion‐weighted imaging of the prostate: Evaluation of a revised monoexponential model within a clinical setting , 2012, Journal of magnetic resonance imaging : JMRI.

[64]  Mark Emberton,et al.  Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.

[65]  Michael Uder,et al.  Magnetic Resonance Image-Guided Biopsies with a High Detection Rate of Prostate Cancer , 2012, TheScientificWorldJournal.

[66]  E. Sala,et al.  The emerging role of diffusion-weighted MRI in prostate cancer management , 2012, Nature Reviews Urology.